The European Strategic Cluster Partnership on Personalized Healthcare, bioXclusters plus – gathering Biocat (Catalonia), BioM (Bavaria), BioPmed (Piedmont) and Lyonbiopole (Auvergne Rhone-Alpes) – organizes in collaboration with the EU Japan Centre a mission to Japan from Oct 10th to 14th 2016. The mission will take place in Osaka and Yokohama.
The delegation is composed by the 4 clusters’ representatives along with 26 SMEs from the bioXclusters plus’ regions:
2bind GmbH, 4SC AG, Ability Pharmaceuticals S.L., Apceth GmbH & Co. KG, Ascenion GmbH, Bioindustry Park Silvano Fumero SpA, Boeters &LieckCoriolis Pharma Research GmbH, CTIBiotech, CYTOO SA, FGK Clinical Research GmbH, Gams Wellness, genOway, Indicia Production, Iris Biotech GmbH, Klifovet AG, Laboratorios Rubió S.A, Laboratorios Salvat S.A., Leukocare AG, Leukos Biotech, Medigene AG, Mind the Byte S.L., Novotec, Theranexus, Thrombotargets Europe S.L., Zeclinics S.L.
An agenda dedicated to SMEs and networking
The company delegation will benefit, on October 10th, from one training day dedicated to acquiring knowledge about the Japanese healthcare sector, organized in cooperation with the EU-Japan Centre. On October 11th, the delegation will participate in a dedicated “European Biotech & Pharma Partnering Conference” organized by bioXclusters plus at the Senri-Life Science Center in Osaka, with the support of Osaka Bio Headquarters and the EU Japan Centre.
On this occasion, more than 150 participants from Japanese and European life sciences and healthcare companies will have the opportunity to network and meet in face-to-face meetings. Around 330 meetings are planned. This unique event has been built up thanks to a growing collaboration between the bioXclusters plus’ partners and its Osaka counterparts.
In the last three days, the full delegation will join the Bio Japan Conference in Yokohama, where European companies will have new opportunities to meet with other Japanese players. The Bio Japan convention is one of the largest event on biotechnologies in Asia, offering multiple business opportunities for companies with around 800 companies participating each year. Moreover, bioXclusters plus will introduce the initiative to Japan during the Bio Cluster summit at Bio Japan, organized by the Japan Bioindustry Association (JBA) on October 13th.
Developing long term strategic partnerships with Japan
Japan is one of the markets targeted by the bioXclusters plus’ alliance. Japan has the 2nd largest global market in healthcare after the US. It is characterized by high health expenditures per capita, the use of advanced technology and a high level of R&D facilities supported by successive development plans of the government.
With an increasingly ageing population, biotechnologies and medical technologies solutions are playing a strategic role in the evolution of the societal and economic challenges advocated by the public authorities from Japan and the European Union in the next years. Moreover, over the past few years, the pharma and medtech industry in Japan have been more and more willing to foster collaborations with external players and in particular with Europe. These factors strongly reinforce the attractiveness of the market for European players in particular SMEs.
For this reason, the bioXclusters plus’ priority is to offer SMEs the right tools to approach such strategic markets by showcasing European competences through a unique delegation united under a single banner maximizing their visibility.
In the next months, the alliance intends to build up a “direct Gateway” based in Japan for its European SMEs to reinforce their market access and foster business relationships with a fast-track dimension.